Konex Bio Venture Anziolab Launches Phase 2 Clinical Trial for Otitis Media Treatment

[Asia Economy Reporter Lim Jeong-su] Angiolab Co., Ltd., a KONEX-listed bio venture company planning to transfer to KOSDAQ, announced on the 22nd that it has officially begun Phase 2 clinical trials of the exudative otitis media treatment 'ALS-L1023.'

Angiolab will start recruiting subjects with exudative otitis media at Chonnam National University Hospital from the 26th. This Phase 2a clinical trial uses random assignment, double-blinding, and placebo control to verify the therapeutic effects of ALS-L1023.

Angiolab plans to orally administer ALS-L1023 to some subjects for six weeks, then evaluate improvements in middle ear effusion volume and tympanic membrane mobility compared to placebo patients to confirm efficacy and assess safety.

According to Angiolab, exudative otitis media is a condition where effusion accumulates in the middle ear cavity. It can occur after acute otitis media or even without infection. It is especially common in children, with a prevalence of 15-20%, and is considered the most common cause of hearing loss.

Currently, there is no treatment, so patients are observed for three months, and if symptoms worsen, treatments such as tympanostomy or middle ear ventilation tube insertion are performed. However, recurrence rates remain high after treatment. In contrast, ALS-L1023 showed not only efficacy but also low side effects and recurrence potential in Phase 1 clinical trials.

Angiolab was founded in 1999. Based on its vascular regeneration discovery technology, it is developing natural product pharmaceuticals and antibody drugs. Phase 2 clinical trials are underway for an oral wet age-related macular degeneration (AMD) treatment and a non-alcoholic steatohepatitis (NASH) treatment, and it recently started Phase 2 trials for a periodontal disease treatment.

Additionally, Angiolab developed Obiex (a lemon balm extract powder blend), a diet supplement recognized by the Ministry of Food and Drug Safety. It is currently sold in domestic hospitals, clinics, and online, and is also exported to Europe. Obiex is a health functional food that inhibits angiogenesis and has the effect of reducing visceral fat.

Meanwhile, Angiolab passed the technology evaluation for KOSDAQ technical special listing in January and plans to pursue a KOSDAQ listing soon.

This content was produced with the assistance of AI translation services.